L
Laura McGreevey
Researcher at Oregon Health & Science University
Publications - 18
Citations - 7009
Laura McGreevey is an academic researcher from Oregon Health & Science University. The author has contributed to research in topics: Imatinib mesylate & Mutation. The author has an hindex of 14, co-authored 18 publications receiving 6715 citations. Previous affiliations of Laura McGreevey include Veterans Health Administration & University of Tübingen.
Papers
More filters
Journal ArticleDOI
PDGFRA Activating Mutations in Gastrointestinal Stromal Tumors
Michael Heinrich,Christopher L. Corless,Anette Duensing,Laura McGreevey,Chang Jie Chen,Nora E. Joseph,Samuel Singer,Diana J. Griffith,Andrea Haley,Ajia Town,George D. Demetri,Christopher D.M. Fletcher,Jonathan A. Fletcher,Jonathan A. Fletcher +13 more
TL;DR: Tumors expressing KIT or PDGFRA oncoproteins were indistinguishable with respect to activation of downstream signaling intermediates and cytogenetic changes associated with tumor progression, suggesting KIT and PDGFra mutations appear to be alternative and mutually exclusive oncogenic mechanisms in GISTs.
Journal ArticleDOI
Kinase Mutations and Imatinib Response in Patients With Metastatic Gastrointestinal Stromal Tumor
Michael Heinrich,Christopher L. Corless,George D. Demetri,Charles D. Blanke,Margaret von Mehren,Heikki Joensuu,Laura McGreevey,Chang Jie Chen,Annick D. Van den Abbeele,Brian J. Druker,Beate Kiese,Burton L. Eisenberg,Peter J. Roberts,Samuel Singer,Christopher D.M. Fletcher,Sandra Silberman,Sasa Dimitrijevic,Jonathan A. Fletcher +17 more
TL;DR: Activating mutations of KIT or PDGFRA are found in the vast majority of GISTs, and the mutational status of these oncoproteins is predictive of clinical response to imatinib.
Journal ArticleDOI
PDGFRA Mutations in Gastrointestinal Stromal Tumors: Frequency, Spectrum and In Vitro Sensitivity to Imatinib
Christopher L. Corless,Arin Schroeder,Diana J. Griffith,Ajia Town,Laura McGreevey,Patina Harrell,Sharon Shiraga,Troy Bainbridge,Jason Morich,Michael Heinrich +9 more
TL;DR: It is suggested that more than one third of GISTs with PDGFRA mutations may respond to imatinib and that mutation screening may be helpful in the management of these tumors.
Journal ArticleDOI
KIT mutations are common in incidental gastrointestinal stromal tumors one centimeter or less in size.
Christopher L. Corless,Christopher L. Corless,Laura McGreevey,Laura McGreevey,Andrea Haley,Andrea Haley,Ajia Town,Ajia Town,Michael Heinrich,Michael Heinrich +9 more
TL;DR: Denaturing high-pressure liquid chromatography is adapted as a method for screening polymerase chain reaction amplimers of exons 9, 11, 13, and 17 from GIST genomic DNA to suggest that KIT mutations per se are of little prognostic importance in GISTs.
Journal ArticleDOI
Activating alleles of JAK3 in acute megakaryoblastic leukemia
Denise K. Walters,Denise K. Walters,Thomas Mercher,Ting-Lei Gu,Thomas O'Hare,Thomas O'Hare,Jeffrey W. Tyner,Marc M. Loriaux,Valerie Goss,Kimberly Lee,Christopher A. Eide,Matthew J. Wong,Eric P. Stoffregen,Laura McGreevey,Julie Nardone,Sandra A. Moore,John D. Crispino,Titus J. Boggon,Michael Heinrich,Michael Heinrich,Michael W. Deininger,Roberto D. Polakiewicz,D. Gary Gilliland,Brian J. Druker,Brian J. Druker +24 more
TL;DR: A screening strategy that rapidly identifies tyrosine-phosphorylated proteins using mass spectrometry allowed the identification of an activating mutation (A572V) in the JAK3 pseudokinase domain in the acute megakaryoblastic leukemia (AMKL) cell line CMK.